Teladoc Health reported Q4 2025 revenue of USD 642.3 million (flat), with net loss of USD 25.1 million and adjusted EBITDA of USD 83.8 million (+12%). For FY 2025, revenue was USD 2.53 billion (-2%), net loss was USD 200.3 million, adjusted EBITDA was USD 281.1 million (-10%), operating cash flow was USD 294.4 million (flat) and free cash flow was USD 166.9 million (-2%); the company ended 2025 with USD 781.1 million in cash and cash equivalents. In Q4, Integrated Care revenue was USD 409.1 million (+5%) while BetterHelp revenue was USD 233.2 million (-7%); Integrated Care adjusted EBITDA was USD 65.3 million (+23%) and BetterHelp adjusted EBITDA was USD 18.5 million (-15%). Teladoc Health said it strengthened its product portfolio and advanced innovation across Integrated Care and BetterHelp, while maintaining a focus on disciplined execution and leveraging technology to meet evolving client and member needs. For FY 2026, Teladoc Health guided for revenue of USD 2.47 billion to USD 2.587 billion and adjusted EBITDA of USD 266 million to USD 308 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teladoc Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477449-26-000010), on February 25, 2026, and is solely responsible for the information contained therein.